Meeting
2021 ASCO Annual Meeting
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.
Authors
Tariqa Ackbarali
PlatformQ Health Education, Needham, MA
Tariqa Ackbarali , Wendy Turell , Elizabeth L. del Nido , Adam Brufsky , Stephen V. Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Professional Development and Education Advances
Track
Medical Education and Professional Development
Sub Track
Education Research
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11036)
DOI
10.1200/JCO.2021.39.15_suppl.11036
Abstract #
11036
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach
First Author: Justin Jee
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox